Aragen Bioscience, Inc., a contract research organization focused on biologics, has formed an agreement with ProteoNic Biotechnology BV, a provider of technology and services in for generating cell lines, for the commercial use of ProteoNic's 2G UNic recombinant protein production technology. Under the deal, Aragen gains the rights to apply this technology to develop recombinant cell lines.

Under the agreement, Aragen will offer cell line development services, including ProteoNic technology for production of biologicals for commercial use under a fee-for-service relationship. The ProteoNic technology is offered without a royalty.

Source: Aragen Biosciences and ProteoNic Biotechnology